J. F. García

Clinical and economic impact of ‘ROS1-testing’ strategy compared to a ‘no-ROS1-testing’ strategy in advanced NSCLC in Spain

F. Rojo, E. Nadal, L. Cabezón-Gutiérrez, 2021, BMC cancer.

Pharmacokinetics of anti‐tuberculosis drugs in Venezuelan children younger than 16 years of age: supportive evidence for the implementation of revised WHO dosing recommendations

R. de Groot, R. Aarnoutse, P. Hermans, 2012, Tropical medicine & international health : TM & IH.

Cost-Effectiveness of Next-Generation Sequencing Versus Single-Gene Testing for the Molecular Diagnosis of Patients With Metastatic Non–Small-Cell Lung Cancer From the Perspective of Spanish Reference Centers

F. López-Ríos, E. de Álava, L. Mezquita, 2023, JCO precision oncology.

Is the combination of pyrazinamide plus rifampicin safe for treating latent tuberculosis infection in persons not infected by the human immunodeficiency virus?

J. Caylà, C. Tortajada, J. Martínez-Lacasa, 2005, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.